Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China
- Executive Order Number
- 14200
- President
- Donald Trump
- Signed
- February 5, 2025
- Published
- February 11, 2025
- Source
- Federal Register
- Original Document
- https://www.govinfo.gov/content/pkg/FR-2025-02-11/pdf/2025-02512.pdf
AI-Generated Summary
Executive Order Summary
Purpose
The purpose of this executive order is to amend a previous executive order concerning the imposition of duties on synthetic opioids from the People’s Republic of China. Specifically, it addresses the duty-free de minimis treatment for certain articles related to the synthetic opioid supply chain.
Key Actions or Directives
- Amendment to Subsection (g) of Section 2: The executive order replaces the existing subsection (g) with a new provision stating that duty-free de minimis treatment under 19 U.S.C. 1321 for covered articles will be available until the Secretary of Commerce notifies the President that adequate systems are in place to process and collect applicable tariffs.
Significant Changes to Policy or Law
- The new provision introduces a conditional end to duty-free de minimis treatment for specified articles. Once the Secretary of Commerce certifies that systems are in place to collect tariffs, the duty-free status will cease.
Potential Impacts
- Government Agencies: The Department of Commerce will need to develop and certify the adequacy of systems for processing and collecting tariffs on the specified articles.
- Citizens and Businesses: Importers and exporters dealing with synthetic opioids may face increased costs once the duty-free treatment ends, potentially affecting the price and availability of these substances.
- International Relations: This could impact trade relations with China, particularly concerning the regulation of synthetic opioids.
Stakeholders Affected
- U.S. Department of Commerce: Responsible for monitoring and certifying the systems for tariff collection.
- Importers and Exporters: Those involved in the trade of synthetic opioids will be directly affected by changes in duty-free treatment.
- People’s Republic of China: As the source of the synthetic opioids, China's trade relations with the U.S. may be impacted.
- Public Health and Safety Agencies: Agencies dealing with opioid-related issues may see changes in the availability and pricing of synthetic opioids.
Legal, Constitutional, or Political Implications
- Legal: The executive order is grounded in several legal authorities, including the International Emergency Economic Powers Act and the National Emergencies Act, indicating its basis in emergency economic measures.
- Constitutional: The order is issued under the President's constitutional authority, ensuring it aligns with executive powers.
- Political: The amendment to the duty-free treatment could be seen as a political move to address the opioid crisis while potentially straining trade relations with China. The order's careful wording to not impair existing legal authorities or create new enforceable rights suggests an intention to minimize legal challenges and political controversy.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.